Biocartis Group NV announced that Biocartis and Genomic Health, Inc. have agreed to terminate their collaboration, which was focused on the development of the Oncotype DX Breast Recurrence Score® test on Biocartis' molecular diagnostics platform Idylla. As a result of COVID-19, the project had been suspended earlier during 2020, with the project plan and timing under evaluation. The decision to now terminate the collaboration was driven by the uncertain timing of a product market release because of the pandemic and a decision by Exact Sciences to shift priorities to other initiatives.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
06-10 | Biocartis Names Chief Business Officer | MT |
06-10 | Biocartis NV Appoints Gina Wallar as Chief Business Officer | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.15M | |
+75.69% | 12.57B | |
+11.44% | 7.03B | |
-30.85% | 6.68B | |
+9.11% | 5.25B | |
-19.22% | 4.67B | |
+19.81% | 4.07B | |
-20.81% | 3.77B | |
-28.74% | 2.66B | |
-2.35% | 1.99B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis Group NV and Biocartis and Genomic Health, Inc. Agree to End Collaboration Due to Changed Market Circumstances